Loading clinical trials...
Loading clinical trials...
Patients with refractory/relapse hematologic oncology disease may benefit from innovative therapy such as Car-T cells. Factors strongly predictive of outcome and response are unknown. Extracellular ve...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT07381933 · Healthy, Extracellular Vesicles
NCT07246304 · Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy
NCT07198867 · Acute Myeloid Leukemia (AML), CAR-T Cell Therapy
NCT05779917 · Pancreas Cancer, CAR-T Cell Therapy, and more
NCT06333275 · Vaccine Immunity in CAR-T Cell Therapy Recipients
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions